ibusinesslines.com March 17, 2018

Oppenheimer Reiterates a Hold Rating on Editas Medicine Inc

13 August 2017, 08:11 | Justin Tyler

The value of the investment in (EDIT) went from $410,000 to $2,513,000 a change of 512.9% for the reporting period. The stock is expected to report revenue as high as $4.4 Million and as low as $0.5 Million per share. Previously Frank's worldwide N.V. (NYSE:FI) reported $-0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.11 by $-0.01 with surprise factor of -9.1%. However a year ago for the same quarter the company has reported $-0.13 EPS. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data. Analysts have placed a $35.2 price target on Editas Medicine, Inc., suggesting a 95.77% gain from recent close.

Editas Medicine, Inc. (EDIT) failed to surprise the stock market in its last reported earnings when it earned -$0.85 a piece versus the consensus-estimated -$0.61. Editas Medicine had a negative return on equity of 63.29% and a negative net margin of 1,864.00%. Of those holders, 70 had increased positions amounting to 5.95 million shares, 30 had decreased positions amounting to 1.65 million shares, and 19 holders have a held position accounting for 20.31 million shares. For the next fiscal year, analysts forecast that the firm will post sales of $24.30 million per share, with estimates ranging from $15.88 million to $39.03 million. The company's quarterly revenue was down 8.8% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on EDIT. Cann reaffirmed a "hold" rating on shares of Editas Medicine in a research report on Thursday. They set a "buy" rating for the company. SunTrust Banks, Inc. initiated coverage on shares of Editas Medicine in a research report on Thursday, July 13th. They set a "hold" rating and a $17.00 price objective for the company. Wall Street is only getting more bullish on the stock, with 3 of analysts who cover EDIT having a buy-equivalent rating. To sum up all these views, EDIT attains Median consensus rating in current rating pool.

WARNING: "Editas Medicine, Inc". If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & worldwide copyright & trademark legislation.

Frank's worldwide N.V. (NYSE:FI) has average revenue estimates of $120.3 Million, compared to low analyst estimates of $114.84 Million and high estimates of $122.4 Million for the current quarter.

In other news, Director Boris Nikolic acquired 35,000 shares of the stock in a transaction that occurred on Friday, June 2nd. Director Boris Nikolic purchased 35,000 shares at an average price of $14.07 on Friday the 2nd. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin Bitterman sold 1,000,000 shares of Editas Medicine stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $17.00, for a total value of $17,000,000.00. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in the stock.

COPYRIGHT VIOLATION NOTICE: "Crestwood Advisors Group LLC Has $2.39 Million Position in Editas Medicine, Inc". State Street Corp now owns 105,167 shares of the company's stock worth $1,708,000 after buying an additional 2,476 shares in the last quarter. Bank of America Corp DE raised its position in shares of Editas Medicine by 72.2% in the first quarter. The company's institutional ownership is monitored at 80.8 percent. Finally, Driehaus Capital Management LLC increased its stake in Editas Medicine by 169.8% in the first quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Editas Medicine by 8.4% in the first quarter. The mean target of $27.00 should be compared with the price when the stock was languishing around $12.43 a share. The firm owned 9,101 shares of the company's stock after buying an additional 9,000 shares during the period.

Insider Trading Activity for Editas Medicine, Inc. The lowest price the stock reached in the last trading day was $78.05 and compares with the $28.35 52-week low. Editas Medicine has a 12 month low of $12.43 and a 12 month high of $29.20. The stock's market cap is $677.69 million. The firm has a 50 day moving average of $16.99 and a 200 day moving average of $18.99. Lastly, Cowen and Company reiterated a "buy" recommendation on stocks of Editas Medicine in a note on Wed, Mar 15th.

Other News

Trending Now

Pentagon Ready to 'Fight Tonight' as Tensions Between US, North Korea Escalate
Things are quickly heating up between the USA and North Korea, and there are no signs it will slow down after the Pentagon said Friday the military stands ready to "fight tonight", if necessary.

Trent Murphy out for the season with torn ACL and MCL
The Redskins also signed free agent wide receiver Jamari Staples on Saturday and waived rookie offensive tackle Kevin Bowen, designated as injured.

Analysts Reveals Updates on AK Steel Holding Corp (AKS)
The company's shares were assimilated at $3.12 per share worth to an investment of some $15,600 on account of Newport Roger K. Timken Steel Corporation ( TMST ) declined 0.12% through out intraday market trading on Early Thur, reaching $15.99.

Christian Hackenberg gives Jets a ray of hope
The highlight of the night was a perfectly-placed, 53-yard pass to Robby Anderson down the right sideline. One of his punts went only 14 yards, and he failed to pin the Titans offense deep in Jets' territory.

Tony Cascarino's club-by-club guide to the new Premier League season
There's a gulf between Albion and City. "The market is so demanding for all the teams, not just Manchester City ". It seems that Arsene Wenger is in last-chance saloon, while Chelsea can't just play one match per week anymore.

Glazers to sell two percent of Manchester United shares
The French midfielder will be looking to link up with Lukaku, his close friend. Then, Mourinho will know whether his work is, once again, on the right track.

Insider Trading at National Retail Properties?
ValuEngine lowered Retail Properties of America from a "buy" rating to a "hold" rating in a research report on Friday, June 2nd. Principal Financial Group Inc. increased its position in Retail Properties of America by 1.4% in the first quarter.